IVA
Inventiva SaNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.04B
P/E Ratio
—
EPS
$-2.22
Beta
0.95
52W High
$7.98
52W Low
$2.85
50-Day MA
$5.89
200-Day MA
$5.12
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Inventiva Sa
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidosis (MPS) and other diseases. The company is headquartered in Daix, France.
Fundamentals
| Revenue (TTM) | $6.76M |
| Gross Profit (TTM) | $6.74M |
| EBITDA | $-132.50M |
| Operating Margin | -6711.00% |
| Return on Equity | -1643.00% |
| Return on Assets | -45.10% |
| Revenue/Share (TTM) | $0.04 |
| Book Value | $-0.17 |
| Price-to-Book | 2.10 |
| Price-to-Sales (TTM) | 153.87 |
| EV/Revenue | 162.65 |
| EV/EBITDA | -1.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -89.90% |
| Shares Outstanding | $207.65M |
| Float | $122.21M |
| % Insiders | 0.00% |
| % Institutions | 25.64% |
Historical Volatility
HV 10-Day
34.09%
HV 20-Day
57.67%
HV 30-Day
56.05%
HV 60-Day
53.46%
HV Rank
11.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($15.13 target)
2
Strong Buy11
BuyData last updated: 4/29/2026